557 related articles for article (PubMed ID: 22726543)
81. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells.
Skrott Z; Cvek B
Mini Rev Med Chem; 2012 Oct; 12(12):1184-92. PubMed ID: 22931589
[TBL] [Abstract][Full Text] [Related]
82. Bortezomib.
Einsele H
Recent Results Cancer Res; 2010; 184():173-87. PubMed ID: 20072838
[TBL] [Abstract][Full Text] [Related]
83. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL
Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731
[TBL] [Abstract][Full Text] [Related]
84. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Vogl DT; Stadtmauer EA; Tan KS; Heitjan DF; Davis LE; Pontiggia L; Rangwala R; Piao S; Chang YC; Scott EC; Paul TM; Nichols CW; Porter DL; Kaplan J; Mallon G; Bradner JE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1380-90. PubMed ID: 24991834
[TBL] [Abstract][Full Text] [Related]
85. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
Stessman HA; Lulla A; Xia T; Mitra A; Harding T; Mansoor A; Myers CL; Van Ness BG; Dolloff NG
Leukemia; 2014 Nov; 28(11):2263-7. PubMed ID: 25005244
[No Abstract] [Full Text] [Related]
86. Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bose P; Batalo MS; Holkova B; Grant S
Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
[TBL] [Abstract][Full Text] [Related]
87. Bortezomib.
Einsele H
Recent Results Cancer Res; 2014; 201():325-45. PubMed ID: 24756802
[TBL] [Abstract][Full Text] [Related]
88. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
89. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Koprivnikar JL; Cheson BD
Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
[TBL] [Abstract][Full Text] [Related]
90. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
[TBL] [Abstract][Full Text] [Related]
91. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
92. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
[TBL] [Abstract][Full Text] [Related]
93. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J
Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524
[TBL] [Abstract][Full Text] [Related]
94. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
95. Bortezomib: proteasome inhibition as an effective anticancer therapy.
Richardson PG; Mitsiades C
Future Oncol; 2005 Apr; 1(2):161-71. PubMed ID: 16555986
[TBL] [Abstract][Full Text] [Related]
96. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
[TBL] [Abstract][Full Text] [Related]
97. Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Niewerth D; Jansen G; Assaraf YG; Zweegman S; Kaspers GJ; Cloos J
Drug Resist Updat; 2015 Jan; 18():18-35. PubMed ID: 25670156
[TBL] [Abstract][Full Text] [Related]
98. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
99. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
100. Proteasome inhibition for antibody-mediated allograft rejection.
Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
